Patents by Inventor Anthony Rossomando
Anthony Rossomando has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10413597Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.Type: GrantFiled: September 29, 2015Date of Patent: September 17, 2019Assignee: ALEXION PHARMACEUTICALS, INC.Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
-
Patent number: 10328125Abstract: Disclosed are methods of improving impaired proprioception, treating brachial plexus injuries, regenerating large and small nerve fibers, treating dorsal root nerve injuries, and improving sensory neural responses in a subject by administration of a neublastin polypeptide.Type: GrantFiled: February 27, 2007Date of Patent: June 25, 2019Assignee: GLORIANA THERAPEUTICS, INC.Inventors: Anthony Rossomando, Frank Porreca, Dinah Wen-Yee Sah
-
Patent number: 10047150Abstract: Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.Type: GrantFiled: January 5, 2015Date of Patent: August 14, 2018Assignee: GLORIANA THERAPEUTICS SARLInventors: Anthony Rossomando, Ping Jin
-
Publication number: 20170216413Abstract: Methods for treating the central nervous system (CNS) in a human patient with mucopolysaccharidosis (MPS) MB who has an intact blood brain barrier, comprising intravenous administration of recombinant NaGlu.Type: ApplicationFiled: September 29, 2015Publication date: August 3, 2017Inventors: Anthony Quinn, Sandra Rojas-Caro, Anthony Rossomando, Robert John Lyng, Kim Lynette Askew, Nelson Hsia, Kiran Patki
-
Publication number: 20150344550Abstract: Antibodies and antigen binding fragments that bind to neublastin polypeptides are disclosed. Also disclosed are methods of using the antibodies and antigen binding fragments in assays for detecting the presence or amount of endogenous and/or exogenous neublastin in a sample and in methods of antagonizing neublastin bioactivity.Type: ApplicationFiled: January 5, 2015Publication date: December 3, 2015Inventors: Anthony Rossomando, Ping Jin
-
Patent number: 9138461Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.Type: GrantFiled: November 16, 2012Date of Patent: September 22, 2015Assignees: Biogen MA Inc., INSERM (Institut National de la Santé et de la Recherche Médicale)Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
-
Patent number: 8969042Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: GrantFiled: March 26, 2014Date of Patent: March 3, 2015Assignee: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
-
Publication number: 20140322752Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: ApplicationFiled: March 26, 2014Publication date: October 30, 2014Applicant: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
-
Publication number: 20140154783Abstract: The present invention relates to molecular biology, molecular genetics, and bioprocessing. The embodiments provide for compositions and methods for producing a biological product, such as an immunogenic agent, in an embryonated egg by introducing into the egg a RNA effector molecule capable of modulating expression of a target gene, wherein the modulation enhances production of the biological product in the egg. These methods provide for RNAi-based approaches to optimize the production of biologics from embryonated eggs, such as the production of viral vaccines including seasonal and pandemic flu vaccines. The invention also relates to molecules, reagents, cells, and kits useful for carrying out the methods, and biological products produced by the methods.Type: ApplicationFiled: July 6, 2010Publication date: June 5, 2014Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, David Kocisko, Muthiah Manogaran, Todd Borland, Shannon Hogan
-
Patent number: 8722862Abstract: Compositions and methods for folding proteins belonging to the transforming growth factor beta superfamily are disclosed. The compositions and methods allow for the folding of such proteins when produced in an expression system that does not yield a properly folded, biologically active product.Type: GrantFiled: August 18, 2005Date of Patent: May 13, 2014Assignee: Biogen Idec MA Inc.Inventors: Anthony Rossomando, R. Blake Pepinsky, BangJian Gong
-
Publication number: 20140099666Abstract: The invention provides compositions and methods for producing a biological product from a host cell. In various embodiments, the biological product is a polypeptide, a metabolite, a nutraceutical, a chemical intermediate, a biofuel, a food additive, or an antibiotic. In one aspect, the invention provides for a method for producing a biological product from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the biological product from the cell, and isolating the biological product from the cell.Type: ApplicationFiled: July 6, 2010Publication date: April 10, 2014Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, David Kocisko, Muthiah Manoharan, Gregory Hinkle, Brian Bettencourt, Shannon Hogan
-
Patent number: 8642732Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: GrantFiled: March 21, 2012Date of Patent: February 4, 2014Assignee: Biogen Idec MA Inc.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando
-
Publication number: 20140004565Abstract: The invention provides compositions and methods for producing an immunogenic agent from a host cell. In various embodiments, the immunogenic agent is a polypeptide, an antigen, a virus particle, or a vaccine In one aspect, the invention provides for a method for producing an immunogenic agent from a host cell. The method generally comprises contacting the cell with a RNA effector molecule, a portion of which is complementary to a target gene, maintaining the cell in a large-scale bioreactor for a time sufficient to modulate expression of the target gene, wherein the modulation enhances production of the immunogenic agent from the cell, and isolating the immunogenic agent from the cell.Type: ApplicationFiled: July 6, 2010Publication date: January 2, 2014Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Anthony Rossomando, Muthiah Manoharan, Gregory Hinkle, Brian Bettencourt, John M. Maraganora, Stuart Pollard, David Kocisko, Shannon Hogan
-
Publication number: 20130237477Abstract: Disclosed are methods of increasing vascularization in a tissue by administering a neublastin polypeptide to a mammal exhibiting impaired or inadequate blood flow in the tissue. The methods can be used to in the treatment or prevention of a disorder characterized by impaired or inadequate blood flow or to increase vascularization in an organ that has been transplanted into a subject.Type: ApplicationFiled: November 16, 2012Publication date: September 12, 2013Applicants: INSERM (Institut de la Sante et de la Recherche Medicale), BIOGEN IDEC MA INC.Inventors: Anthony Rossomando, Jean-Sebastien Silvestre, Radia Tamarat
-
Publication number: 20130196410Abstract: Provided herein are methods and compositions for expressing a modified polypeptide in a host cell, wherein the modified polypeptide comprises a terminal mannose at an N-linked glycosylation site of the polypeptide. The methods and compositions used herein involve the use of RNA effector molecules (e.g., siRNA, dsRNA etc) administered to a host cell to modify the expression of target genes involved in protein glycosylation (e.g., Mgat1, Mgat4, SLC35A1, SLC35A2 or GNE).Type: ApplicationFiled: March 3, 2011Publication date: August 1, 2013Applicant: ALNYLAM PHARMACEUTICALS, INCInventor: Anthony Rossomando
-
Publication number: 20130164851Abstract: Provided herein are methods and compositions for generating a cell line capable of producing a biological product, using a gene amplification based system. Methods and compositions are provided to inhibit endogenous selectable amplifiable marker genes using RNA interference and prevent the selection of false positives during generation of a custom cell line. Such methods improve efficiency of cell line development and do not require the use of specialized substrates or cells lacking the endogenous selectable amplifiable marker gene to negate the effect of endogenously expressed levels of the selectable amplifiable marker gene in cells.Type: ApplicationFiled: March 25, 2011Publication date: June 27, 2013Applicant: ALNYLAM PHARMACEUTICALS, INC.Inventors: Anthony Rossomando, Gregory P. Thill, Stuart Pollard
-
Publication number: 20130164329Abstract: The present invention relates to compositions and methods for isolating cells devoid of unwanted viral contaminants, and to methods for preparing a virus stock substantially devoid of viral contaminants. Virus stocks, cells, and immunogenic reagents produced using such methods are also provided.Type: ApplicationFiled: February 16, 2011Publication date: June 27, 2013Applicant: Alnylam Pharmaceuticals, Inc.Inventors: Anthony Rossomando, John M. Maraganore, Stuart Pollard, Muthiah Manoharan
-
Publication number: 20130109624Abstract: The invention relates to neublastin neurotrophic factor polypeptides, nucleic acids encoding neublastin polypeptides, and antibodies that bind specifically to neublastin polypeptides, as well as methods of making and methods of using the same.Type: ApplicationFiled: June 27, 2012Publication date: May 2, 2013Applicants: NSGENE A/S, BIOGEN IDEC MA INC.Inventors: Dinah W.Y. Sah, Teit E. Johansen, Anthony Rossomando
-
Publication number: 20130096065Abstract: Variant Neublastin polypeptides having substitutions at selected amino acid residues are disclosed. Substitution at one or more selected amino acid residues decreases heparin binding and increases serum exposure of variant Neublastin polypeptides. Also disclosed are methods of using variant Neublastin polypeptides to treat disorders and activate the RET receptor in a mammal.Type: ApplicationFiled: July 3, 2012Publication date: April 18, 2013Applicant: BIOGEN IDEC MA INC.Inventors: Anthony Rossomando, Laura Silvian, R. Blake Pepinsky
-
Publication number: 20120316109Abstract: The following class of molecule is disclosed: a dimer containing a first neublastin polypeptide and a second neublastin polypeptide, wherein: (a) at least one of the polypeptides is glycosylated; (b) at least one of the polypeptides is conjugated at its N-terminus to a water-soluble synthetic polymer; and (c) neither of the polypeptides is conjugated to a water-soluble synthetic polymer at a position other than the N-terminus. Such dimers possess the biological activity of wild-type neublastin while displaying enhanced serum half-life and enhanced potency relative to wild-type neublastin.Type: ApplicationFiled: March 21, 2012Publication date: December 13, 2012Applicant: BIOGEN IDEC MA INC.Inventors: Dinah Wen-Yee Sah, R. Blake Pepinsky, Anthony Rossomando